Arsanis
is a biotechnology company that develops novel monoclonal antibody immunotherapies for cancer, pneumonia, urosepsis and other infectious diseases... Read moreArsanis
is a biotechnology company that develops novel monoclonal antibody immunotherapies for cancer, pneumonia, urosepsis and other infectious diseases... Read more
News
Mar 14, 2019
The Pharma Letter
Arsanis: X4 Pharma completes reverse merger with Arsanis
Mar 14, 2019
Benzinga
Arsanis: The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
Jan 12, 2019
Zolmax News
Arsanis: Brokerages Set Arsanis Inc (ASNS) PT at $14.25
Dec 12, 2018
X News Press
Arsanis: -$0.61 EPS Expected for Arsanis Inc (ASNS) This Quarter
Nov 28, 2018
The Business Journals
Arsanis: Arsanis may face more layoffs after merger with X4 Pharma
Nov 28, 2018
Market Exclusive
Arsanis: Arsanis,Inc. (NASDAQ: ASNS) Files An 8-K Entry into a Material Definitive Agreement
Nov 27, 2018
BioPortfolio
Arsanis: Arsanis went public 12 months ago. Is this a record for time from IPO to extinction httpstwitter.comjohncendptsstatus1067444464539615234Â
Nov 21, 2018
BioPortfolio
Arsanis: Arsanis Inc ASNS Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23102018 Prices from USD $250
Nov 09, 2018
4-traders
Arsanis: Arsanis Reports Financial Results for Third Quarter 2018
Aug 13, 2018
GlobeNewswire
Press Release: Arsanis : Arsanis Reports Financial Results for Second Quarter 2018
Arsanis Competitors
1
2
3
4
5
6
7
8
9
10